Publication | Closed Access

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

HypertensionHeart FailureCardiorenal SyndromesCardiovascular DiseaseAntihypertensive TherapyCardiovascular PharmacologyPreserved Ejection FractionPharmacotherapyPhase 2MedicineCardiologyDiastolic FunctionAnesthesiology